244 related articles for article (PubMed ID: 28070196)
1. Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy.
Mukherjee M; Lim HF; Thomas S; Miller D; Kjarsgaard M; Tan B; Sehmi R; Khalidi N; Nair P
Allergy Asthma Clin Immunol; 2017; 13():2. PubMed ID: 28070196
[TBL] [Abstract][Full Text] [Related]
2. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
3. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma.
Sehmi R; Smith SG; Kjarsgaard M; Radford K; Boulet LP; Lemiere C; Prazma CM; Ortega H; Martin JG; Nair P
Clin Exp Allergy; 2016 Jun; 46(6):793-802. PubMed ID: 26685004
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.
Mukherjee M; Forero DF; Tran S; Boulay ME; Bertrand M; Bhalla A; Cherukat J; Al-Hayyan H; Ayoub A; Revill SD; Javkar T; Radford K; Kjarsgaard M; Huang C; Dvorkin-Gheva A; Ask K; Olivenstein R; Dendukuri N; Lemiere C; Boulet LP; Martin JG; Nair P
Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32444405
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab: 240563, anti-IL-5 monoclonal antibody - GlaxoSmithKline, anti-interleukin-5 monoclonal antibody - GlaxoSmithKline, SB 240563.
Drugs R D; 2008; 9(2):125-30. PubMed ID: 18298130
[TBL] [Abstract][Full Text] [Related]
6. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab and eosinophil-mediated disease.
Walsh GM
Curr Med Chem; 2009; 16(36):4774-8. PubMed ID: 19929788
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
10. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
Gupta A; Ikeda M; Geng B; Azmi J; Price RG; Bradford ES; Yancey SW; Steinfeld J
J Allergy Clin Immunol; 2019 Nov; 144(5):1336-1342.e7. PubMed ID: 31425781
[TBL] [Abstract][Full Text] [Related]
11. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma.
Kelly EA; Esnault S; Liu LY; Evans MD; Johansson MW; Mathur S; Mosher DF; Denlinger LC; Jarjour NN
Am J Respir Crit Care Med; 2017 Dec; 196(11):1385-1395. PubMed ID: 28862877
[TBL] [Abstract][Full Text] [Related]
13. Sputum autoantibodies in patients with severe eosinophilic asthma.
Mukherjee M; Bulir DC; Radford K; Kjarsgaard M; Huang CM; Jacobsen EA; Ochkur SI; Catuneanu A; Lamothe-Kipnes H; Mahony J; Lee JJ; Lacy P; Nair PK
J Allergy Clin Immunol; 2018 Apr; 141(4):1269-1279. PubMed ID: 28751233
[TBL] [Abstract][Full Text] [Related]
14. A real life cohort of Mepolizumab treatment in severe eosinophilic asthma.
Laorden D; Hernández I; Domínguez-Ortega J; Romero D; Álvarez-Sala R; Quirce S
Eur Ann Allergy Clin Immunol; 2023 Mar; ():. PubMed ID: 36927725
[No Abstract] [Full Text] [Related]
15. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
16. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Chupp GL; Bradford ES; Albers FC; Bratton DJ; Wang-Jairaj J; Nelsen LM; Trevor JL; Magnan A; Ten Brinke A
Lancet Respir Med; 2017 May; 5(5):390-400. PubMed ID: 28395936
[TBL] [Abstract][Full Text] [Related]
18. Mepolizumab treatment for asthma.
Robinson DS
Expert Opin Biol Ther; 2013 Feb; 13(2):295-302. PubMed ID: 22998420
[TBL] [Abstract][Full Text] [Related]
19. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
20. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]